Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation

医学 围手术期 桥接(联网) 华法林 心房颤动 麻醉 低分子肝素 安慰剂 外科 随机对照试验 抗凝剂 肝素 心脏病学 计算机网络 替代医学 病理 计算机科学
作者
James D. Douketis,Alex C. Spyropoulos,Scott Kaatz,Richard C. Becker,Joseph A. Caprini,Andrew Dunn,David García,Alan K. Jacobson,Amir K. Jaffer,David F. Kong,Sam Schulman,Alexander G.G. Turpie,Vic Hasselblad,Thomas L. Ortel
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:373 (9): 823-833 被引量:1182
标识
DOI:10.1056/nejmoa1501035
摘要

BACKGROUND: It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasive procedure. We hypothesized that forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight heparin for the prevention of perioperative arterial thromboembolism and would be superior to bridging with respect to major bleeding. METHODS: We performed a randomized, double-blind, placebo-controlled trial in which, after perioperative interruption of warfarin therapy, patients were randomly assigned to receive bridging anticoagulation therapy with low-molecular-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure. Warfarin treatment was stopped 5 days before the procedure and was resumed within 24 hours after the procedure. Follow-up of patients continued for 30 days after the procedure. The primary outcomes were arterial thromboembolism (stroke, systemic embolism, or transient ischemic attack) and major bleeding. RESULTS: In total, 1884 patients were enrolled, with 950 assigned to receive no bridging therapy and 934 assigned to receive bridging therapy. The incidence of arterial thromboembolism was 0.4% in the no-bridging group and 0.3% in the bridging group (risk difference, 0.1 percentage points; 95% confidence interval [CI], -0.6 to 0.8; P=0.01 for noninferiority). The incidence of major bleeding was 1.3% in the no-bridging group and 3.2% in the bridging group (relative risk, 0.41; 95% CI, 0.20 to 0.78; P=0.005 for superiority). CONCLUSIONS: In patients with atrial fibrillation who had warfarin treatment interrupted for an elective operation or other elective invasive procedure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molecular-weight heparin for the prevention of arterial thromboembolism and decreased the risk of major bleeding. (Funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health; BRIDGE ClinicalTrials.gov number, NCT00786474.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fantasy的应助被巡山的K采纳,获得10
刚刚
刚刚
Reader完成签到,获得积分10
1秒前
斯文败类的应助被好家伙采纳,获得10
1秒前
1秒前
1秒前
1秒前
shilong.yang完成签到,获得积分10
1秒前
勤恳澜完成签到 ,获得积分10
1秒前
科研通AI6.3的应助被dddddd采纳,获得10
2秒前
ZhaoYX完成签到 ,获得积分10
3秒前
Walker发布了新的文献求助10
3秒前
李云穆完成签到,获得积分10
4秒前
梦meng完成签到,获得积分10
5秒前
www发布了新的文献求助10
5秒前
5秒前
csd发布了新的文献求助100
5秒前
jlhqw187完成签到 ,获得积分20
5秒前
6秒前
6秒前
7秒前
刻苦慕灵完成签到,获得积分10
7秒前
Akim的应助被zyy采纳,获得30
7秒前
7秒前
aujsdhab完成签到,获得积分10
7秒前
hx完成签到 ,获得积分10
7秒前
欢子12321完成签到,获得积分10
7秒前
斯文败类的应助被乐鱼采纳,获得10
8秒前
ccdw完成签到,获得积分10
9秒前
10秒前
称心的绿竹完成签到,获得积分10
10秒前
10秒前
亭亭发布了新的文献求助10
10秒前
充电宝的应助被酷酷班采纳,获得10
10秒前
乐大帅完成签到,获得积分10
10秒前
11秒前
yolo完成签到 ,获得积分10
11秒前
12秒前
无敌关注了科研通微信公众号
12秒前
liuz53完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181379
求助须知:如何正确求助?哪些是违规求助? 9571317
关于积分的说明 21817457
捐赠科研通 7777820
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479523